Adenocarcinoma

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Full results will be presented as a late-breaking ASCO GI talk on Jan. 8 ahead of anticipated regulatory evaluation.